Antibodies News and Research

RSS

Engineering nanobodies to fight against the SARS-CoV-2 virus

Scientists are pursuing a new strategy in the protracted fight against the SARS-CoV-2 virus by engineering nanobodies that can neutralize virus variants in two different ways.

22 Jun 2021

Do the Moderna and Pfizer COVID-19 vaccines elicit different antibody responses?

A recent study led by scientists from the United States has compared the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response among clinicians who have been immunized with Pfizer/BioNTech or Moderna coronavirus disease 2019 (COVID-19) vaccine.

22 Jun 2021

What is the optimal dosing regimen for remdesivir in COVID-19 patients? A computational model

A team of scientists from the Pennsylvania State University, USA, recently analyzed the pharmacodynamics and pharmacokinetics of antiviral drug remdesivir using computational models. Based on the study findings, which are yet to be peer-reviewed, the scientists recommend that for effective inhibition of SARS-CoV-2 infection, remdesivir should be used with other antiviral medicines, or its dosing regimen should be optimized to improve bioavailability.

22 Jun 2021

Is Rand Paul mixing up the vaccine message for Covid survivors?

Last week, Sen. Rand Paul (R-Ky.) posted a Twitter thread asserting that people who have survived a Covid-19 infection were unlikely to be reinfected and have better immunity against variants than those who have been vaccinated against — but not infected by — SARS-CoV-2, the virus that causes Covid.

22 Jun 2021

Use of nanotherapeutics in treating coronavirus diseases

Despite advancements in medicine, viral infections still pose a huge threat to human health and are a significant concern for global public health systems.

22 Jun 2021

Study: Immune responses may develop against other proteins produced by SARS-CoV-2

All coronaviruses produce four primary structural proteins and multiple nonstructural proteins. However, the majority of antibody-based SARS-CoV-2 research has focused on the spike and nucleocapsid proteins.

22 Jun 2021

Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

COVID-19 therapies made from antibodies often are given to patients who are at high risk of severe illness and hospitalization. However, there have been nagging questions about whether such antibody therapies retain their effectiveness as worrisome new virus variants arise.

21 Jun 2021

Researchers uncover the role of macrophages in liver growth after massive resections

RUDN University doctors found out what role macrophages play in the recovery of the liver after the removal of its significant part. The results are published in the journal Biomedicine & Pharmacotherapy.

21 Jun 2021

Study shows a robust immune response to COVID-19 vaccine in breastfeeding health workers

A recent study by researchers from Poland, published in the journal Vaccines, shows how levels of IgA and IgG antibodies specific to the spike glycoprotein of SARS-CoV-2 increase in both breast milk and serum samples of mothers following vaccination against COVID-19 – with important implications for further vaccine planning endeavors.

21 Jun 2021

Multivalent antibodies show high potency against SARS-CoV-2 in new study

A new study in the journal Nature Communications describes the process of converting a SARS-CoV-2 antibody into a multivalent form, thus enabling it to bind at various different points with its epitope.

21 Jun 2021

A World First: sequencing polyclonal antibodies using only proteomics

News-Medical speaks to Bin Ma, President of Rapid Novor, about their latest research that sequenced polyclonal antibodies using only proteomics.

From Rapid Novor Inc 21 Jun 2021

COVID-19 studies should provide sex-disaggregated data, researchers warn

Researchers have warned that studies examining sex-specific responses to infection with SARS-CoV-2 must provide sex-disaggregated data.

21 Jun 2021

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

In a recent study, a group of researchers aimed to identify exactly how early SARS-CoV-2 was circulating throughout the United States.

21 Jun 2021

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

A recent study discusses the findings of a study on patients with hematologic cancers who received convalescent plasma therapy following their diagnosis of COVID-19.

21 Jun 2021

Blocking IL-11 signaling can promote liver regeneration after paracetamol-induced damage

Scientists at Duke-NUS Medical School and National Heart Centre Singapore, in collaboration with colleagues in Singapore and the UK, have shown that the human form of the signaling protein interleukin 11 (IL-11) has a damaging effect on human liver cells--overturning a prior hypothesis that it could help livers damaged by paracetamol poisoning.

18 Jun 2021

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

A team of scientists from the United States has recently revealed the antiviral efficacy of stem-loop RNA 14, a RIG-1 agonist, in controlling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice. The compound reduces the risk of severe coronavirus disease 2019 (COVID-19) by inhibiting viral replication in the lower respiratory tract. The study is currently available on the bioRxiv* preprint server.

18 Jun 2021

Combination of interferon-α and nafamostat inhibits SARS-CoV-2 in vivo

A new study, released as a preprint on bioRxiv* server, shows that a combination of the biological interferon-α and the small molecule nafamostat are effective against SARS-CoV-2 infection in vitro, as well as in vivo.

18 Jun 2021

COVID-19 outbreak in Mauritius dominated by new SARS-CoV-2 variant B.1.1.318

Underlining the key role of genomic surveillance in keeping tabs on the spread of SARS-CoV-2, a new medRxiv* preprint shows how a new variant called B.1.1.318 rose to dominance in the small island country of Mauritius, in the Indian Ocean.

18 Jun 2021

Could horse-derived antibody therapy be effective against SARS-CoV-2 variants of concern?

A new study, released as a preprint on the bioRxiv* server, reveals the high neutralizing efficacy of hyperimmune horse serum against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could prove, if validated, to be a more affordable yet potent therapeutic in reducing the morbidity and mortality caused by this virus.

18 Jun 2021

First insights into human prion disease could help tackle neurodegenerative diseases

Surface features of human prions have been identified for the first time, which may provide key information into treatments of neurodegenerative diseases.

18 Jun 2021

Antibodies News and Research

Engineering nanobodies to fight against the SARS-CoV-2 virus

Do the Moderna and Pfizer COVID-19 vaccines elicit different antibody responses?

What is the optimal dosing regimen for remdesivir in COVID-19 patients? A computational model

Is Rand Paul mixing up the vaccine message for Covid survivors?

Use of nanotherapeutics in treating coronavirus diseases

Study: Immune responses may develop against other proteins produced by SARS-CoV-2

Dual-antibody combination therapies effective against SARS-CoV-2 variants in animal study

Researchers uncover the role of macrophages in liver growth after massive resections

Study shows a robust immune response to COVID-19 vaccine in breastfeeding health workers

Multivalent antibodies show high potency against SARS-CoV-2 in new study

A World First: sequencing polyclonal antibodies using only proteomics

COVID-19 studies should provide sex-disaggregated data, researchers warn

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

Blocking IL-11 signaling can promote liver regeneration after paracetamol-induced damage

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

Combination of interferon-α and nafamostat inhibits SARS-CoV-2 in vivo

COVID-19 outbreak in Mauritius dominated by new SARS-CoV-2 variant B.1.1.318

Could horse-derived antibody therapy be effective against SARS-CoV-2 variants of concern?

First insights into human prion disease could help tackle neurodegenerative diseases

Antibodies eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News